This $1,399,501 federal Project Grant awarded by the Defense Health Agency on September 1, 2023 will fund the development of a novel DNA aptamer-based IFN-γ targeted therapy for chronic cystitis pain at the University of Iowa. The project, which is scheduled for completion by August 31, 2027, aligns with the objectives of the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to transform healthcare for Service Members and the American public through innovative biomedical research. The University of Iowa, a top public research institution, has a proven track record of successfully executing diverse federal research, healthcare, and specialized service contracts and grants for agencies like the NIH, NSF, and VA. This award will leverage the university's expertise across relevant research departments and core facilities to advance the development of this promising new therapeutic approach for managing a painful chronic condition.
Generated 6/11/24, 10:09 AM